BioAge Labs Earnings Estimate

BIOA Stock   20.69  2.84  15.91%   
The next projected EPS of BioAge Labs is estimated to be -0.649 with future projections ranging from a low of -0.74 to a high of -0.55. BioAge Labs' most recent 12-month trailing earnings per share (EPS TTM) is at 13.61. Please be aware that the consensus of earnings estimates for BioAge Labs is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
BioAge Labs is projected to generate -0.649 in earnings per share on the 31st of March 2026. BioAge Labs earnings estimates show analyst consensus about projected BioAge Labs EPS (Earning Per Share). It derives the highest and the lowest estimates based on BioAge Labs' historical volatility. Many public companies, such as BioAge Labs, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing BioAge Labs' earnings estimates, investors can diagnose different trends across BioAge Labs' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about (6.3 M)Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioAge Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.

BioAge Labs Earnings Estimation Breakdown

The calculation of BioAge Labs' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BioAge Labs is estimated to be -0.649 with the future projection ranging from a low of -0.74 to a high of -0.55. Please be aware that this consensus of annual earnings estimates for BioAge Labs is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
-0.74
Lowest
Expected EPS
-0.649
-0.55
Highest

BioAge Labs Earnings Projection Consensus

Suppose the current estimates of BioAge Labs' value are higher than the current market price of the BioAge Labs stock. In this case, investors may conclude that BioAge Labs is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and BioAge Labs' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2026Current EPS (TTM)
40.0%
0.0
-0.649
13.61

BioAge Labs Earnings per Share Projection vs Actual

Actual Earning per Share of BioAge Labs refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering BioAge Labs predict the company's earnings will be in the future. The higher the earnings per share of BioAge Labs, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

BioAge Labs Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as BioAge Labs, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of BioAge Labs should always be considered in relation to other companies to make a more educated investment decision.

BioAge Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact BioAge Labs' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
2025-11-06
2025-09-30-0.5137-0.56-0.0463
2025-08-06
2025-06-30-0.3814-0.6-0.218657 
2025-05-06
2025-03-31-0.5276-0.360.167631 
2025-03-20
2024-12-31-0.655-1.0-0.34552 
2024-11-07
2024-09-30-0.7343-6.7-5.9657812 
2024-08-28
2024-06-300-0.6-0.6

About BioAge Labs Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of BioAge Labs earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current BioAge Labs estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as BioAge Labs fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-227.5 M-238.9 M
Earnings Yield(1.32)(1.38)
Price Earnings Ratio(0.79)(0.83)
Price Earnings To Growth Ratio 0.04  0.04 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether BioAge Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioAge Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioage Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioage Labs Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioAge Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
13.61
Revenue Per Share
0.165
Return On Assets
(0.17)
Return On Equity
(0.26)
The market value of BioAge Labs is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs' value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs' market value can be influenced by many factors that don't directly affect BioAge Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.